STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease
- PMID: 21752694
- DOI: 10.1016/j.cytogfr.2011.06.003
STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease
Abstract
Inflammation participates importantly in host defenses against infectious agents and injury, but it also contributes to the pathophysiology of atherosclerosis. Recruitment of blood leukocytes to the injured vascular endothelium characterizes the initiation and progression of atherosclerosis and involves many inflammatory mediators, modulated by cells of both innate and adaptive immunity. The pro-inflammatory cytokine, interferon (IFN)-γ derived from T cells, is vital for both innate and adaptive immunity and is also expressed at high levels in atherosclerotic lesions. As such IFN-γ plays a crucial role in the pathology of atherosclerosis through activation of signal transducer and activator of transcription (STAT) 1. Toll-like receptors (TLRs) are innate immune pattern recognition receptors (PRRs) expressed on a variety of cells, and thus initiate and sustain the inflammatory response in atherosclerosis. More recent studies have revealed that STAT1 is involved in the signaling events mediated by TLR4, leading to increased expression of several pro-inflammatory and pro-atherogenic mediators. By upregulating members of the Suppressors Of Cytokine Signaling (SOCS) family that regulate cellular responsiveness to immune signals, IFNγ and TLR4-activated pathways have also shown to inhibit IL-6 STAT3-dependent anti-inflammatory signaling and potentially shift IL-6 to a STAT1 activating pro-inflammatory cytokine. Consequently, STAT1 has been identified as a point of convergence for the cross-talk between the pro-atherogenic IFN-γ, TLR4 and IL-6 activated pathways in immune as well as vascular cells, as such amplifying pro-inflammatory signals. This results in augmented smooth muscle cell (SMC) and leukocyte migration, leukocyte to endothelial cell (EC) adhesion and foam cell formation, and could encompass a novel mechanism involved in the initiation and progression of atherosclerosis. Therefore, application of small inhibitory compounds that specifically interact with the SH2-phosphotyrosine pocket of STAT1, proposed here as a novel working mechanism for the known STAT1 inhibitor fludarabine, could be a promising tool in the development of a therapeutical strategy for atherosclerosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion.Am J Physiol Cell Physiol. 2011 Jun;300(6):C1337-44. doi: 10.1152/ajpcell.00276.2010. Epub 2011 Feb 23. Am J Physiol Cell Physiol. 2011. PMID: 21346151
-
Signal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NFκB to Enhance Pro-inflammatory Transcription.Front Immunol. 2019 Jun 4;10:1253. doi: 10.3389/fimmu.2019.01253. eCollection 2019. Front Immunol. 2019. PMID: 31231385 Free PMC article.
-
Suppressor of cytokine signaling and accelerated atherosclerosis in kidney disease.Acta Biochim Pol. 2010;57(3):251-60. Epub 2010 Aug 19. Acta Biochim Pol. 2010. PMID: 20725646 Review.
-
Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ.Basic Res Cardiol. 2011 Mar;106(2):217-31. doi: 10.1007/s00395-010-0141-0. Epub 2010 Dec 21. Basic Res Cardiol. 2011. PMID: 21174212
-
STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential.Int Rev Immunol. 2016 Sep 2;35(5):434-454. doi: 10.3109/08830185.2015.1087519. Epub 2015 Nov 25. Int Rev Immunol. 2016. PMID: 26606328 Review.
Cited by
-
STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction.JAKSTAT. 2012 Oct 1;1(4):241-9. doi: 10.4161/jkst.22469. JAKSTAT. 2012. PMID: 24058779 Free PMC article. Review.
-
STAT3/NF‑κB decoy oligodeoxynucleotides inhibit atherosclerosis through regulation of the STAT/NF‑κB signaling pathway in a mouse model of atherosclerosis.Int J Mol Med. 2023 May;51(5):37. doi: 10.3892/ijmm.2023.5240. Epub 2023 Apr 7. Int J Mol Med. 2023. PMID: 37026512 Free PMC article.
-
Macrophage molecular signaling and inflammatory responses during ingestion of atherogenic lipoproteins are modulated by complement protein C1q.Atherosclerosis. 2016 Oct;253:38-46. doi: 10.1016/j.atherosclerosis.2016.08.019. Epub 2016 Aug 22. Atherosclerosis. 2016. PMID: 27573737 Free PMC article.
-
Advances in targeting 'undruggable' transcription factors with small molecules.Nat Rev Drug Discov. 2021 Sep;20(9):669-688. doi: 10.1038/s41573-021-00199-0. Epub 2021 May 18. Nat Rev Drug Discov. 2021. PMID: 34006959 Review.
-
A novel role of peroxiredoxin 2 in diabetic kidney disease progression by activating the classically activated macrophages.Sci Rep. 2024 Nov 16;14(1):28258. doi: 10.1038/s41598-024-79678-4. Sci Rep. 2024. PMID: 39550424 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous